• In June 2026, Helus Pharma reported that enrollment in Cybin’s APPROACH Phase 3 trial of HLP003 for adjunctive major depressive disorder surpassed 86%, advancing a program that holds FDA Breakthrough Therapy Designation and builds on earlier positive Phase 2 clinical outcomes.
• This late-stage progress, alongside previously reported long-term efficacy signals, highlights how HLP003 could further shape Cybin’s pipeline profile if Phase 3 results are supportive.
• We’ll now examine how this advanced Phase 3 enrollment milestone for HLP003 might influence Cybin’s existing investment narrative around late-stage psychiatric treatments.

The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Cybin Investment Narrative Recap

To own Cybin, you need to believe that late stage psychedelic based treatments for depression can convert into approved products and clinic adoption. The key near term catalyst remains Phase 3 readouts for HLP003 in major depressive disorder, while the biggest risk is ongoing cash burn and potential dilution if timelines extend. The 86% enrollment milestone helps de risk trial execution, but does not remove the underlying clinical and financing uncertainties in the story.

The follow on equity offering completed on 24 June 2026, raising about US$50.0 million, sits alongside this Phase 3 progress. It directly connects to the same catalyst by giving Cybin more room to fund the PARADIGM program, including APPROACH, EMBRACE and EXTEND, but it also reinforces dilution risk for existing shareholders as the company continues to issue new shares ahead of any revenue.

Yet while Phase 3 progress is encouraging, investors should also be aware that...

Cybin's narrative projects $174.0 million in revenue and $37.4 million in earnings by 2029. This implies an earnings increase of about $160.6 million from -$123.2 million today.

Uncover how Cybin's forecasts yield a $49.46 fair value, a 722% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were once penciling in about US$170.2 million of revenue and US$34.1 million of earnings by 2029, so if you focus on how HLP003 enrollment progress interacts with that kind of growth outlook, you can see how opinions about Cybin’s risk and reward can differ a lot and may keep shifting as new data arrives.

Explore 6 other fair value estimates on Cybin - why the stock might be a potential multi-bagger!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Cybin research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.
• Our free Cybin research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Cybin's overall financial health at a glance.

No Opportunity In Cybin?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Uncover the next big thing with 22 elite penny stocks that balance risk and reward.
• This technology could replace computers: discover 30 stocks that are working to make quantum computing a reality.
• Find 43 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.